Biogen seeks OK for Alzheimer's drug

A US company says it has created the first drug to slow Alzheimer's disease and will seek regulatory approval in 2020 from the US Food and Drug Administration, or FDA.

Biogen, a Cambridge, Massachusetts-based company, said its drug containing the antibody aducanumab could slow the effects of early onset Alzheimer's, limiting severe memory loss.

"This could be a game-changer," said an executive scientist with the Alzheimer's Association. "We are very hopeful."